Investing in Psychedelics with MindMed Stock

March 23. 2021. 6 mins read

It was the late Robin Williams who once said, “Reality is just a crutch for people who can’t handle drugs.” What D.A.R.E. didn’t tell kids was how much fun drugs can be. If approached with a certain degree of responsibility, some universal truths start to emerge. Heroin is deadly and best avoided entirely. Cannabis is harmless compared to alcohol. When you’re a bit too drunk, coke is a great way to sober up. Meth is a rush, but you’ll always be chasing that first high. And everyone should try LSD once in their lifetimes.

Society has been taking an increasingly lax approach to drug use lately as the Americans are legalizing them left and right. In turn, this has created a whole new class of pharmaceutical companies that hope to unleash the power of hallucinogens like mushrooms and LSD. In turn, that’s drawn the attention of investors who think there’s a lot of potential for investing in psychedelics.

Investing in Psychedelics

Just months ago, the world’s first psychedelic ETF went live. With about $65 million in assets under management, the Horizons Psychedelic Stock Index ETF (PSYK.NE) comes with a steep management fee of 0.85%. The ETF tracks the North American Psychedelics Index which is produced by index provider Solactive. The belo

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.